EUCTR2016-005251-25-IT进行中（未招募）1 期
CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, prospective, two-arm, open label, non inferiority phase II study. - CABACARE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Signed informed consent.
- •2. Histological diagnosis of prostate adenocarcinoma;
- •3. Metastatic castration-resistant disease with documented radiographic progression (osseous or measurable lesions) during or after a docetaxel-based chemotherapy;
- •4. Testosterone level in the castration range (levels <50 ng/dl) because of a previous, and ongoing, androgen deprivation with LH-RH agonists or antagonists or bilateral orchiectomy;
- •5. Prior surgery and/or radiation therapy (to less or equal than 30% of the bone marrow) are allowed. However, at least 4 weeks must have been elapsed since surgery or completion of radiation therapy and the patient must has recovered from side effects;
- •6. Life expectancy = 3 months;
- •7. Age > 18 years;
- •8. ECOG performance status 0-2;
- •9. ANC = 1.5 x 109/L;
- •10. PLT = 100 x 109/L;
- •11. Hb = 10 g/dl;
- •12. Serum total bilirubin = UNL;
- •13. AST/SGOT and/or ALT/SGPT =1,5 x ULN;
- •14. Serum Creatinine =1,5 times UNL (in case of limit values of serum creatinine, creatinine clearance calculated by CKD-EPI formula should be =60 ml/min);
- •15. PT or INR and PTT <1,5 times UNL (Note: patients who receive anti-coagulation treatment will be allowed to participate provided that any abnormality in these parameters exists);
- •16. Patients must be accessible for treatment and follow up;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 66
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 154
排除标准
- •1. Participation in clinical trials with other investigational drug within 28 days of study entry;
- •2. Symptomatic or uncontrolled brain metastases. Patients with neurological symptoms must undergo a computed tomography (CT) scan/magnetic resonance imaging (MRI) of the brain to exclude brain metastasis; previously treated brain metastases will be allowed as long as the patient is neurologically stable and does not require steroids and anticonvulsants;
- •3. Less than 4 weeks elapsed from prior anticancer-therapy or surgery to the time of randomization. Patient may be on bisphosphonates prior to study entry. Prior treatment with abiraterone or enzalutamide is allowed and is used as a stratification factor at randomization. Patient may be on biphosphonates prior to study entry;
- •4. Less than 4 weeks from palliative Radiotherapy to time of randomization;
- •5. Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack, pulmonary embolism or other uncontrolled thromboembolic event;
- •6. Any severe acute or chronic medical condition which could impair the ability of the patient to participate to the study or interfere with interpretation of study results, or patient unable to comply with the study procedures;
- •7. Unstable diabetes mellitus, resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, acute diverticulitis or other contraindications to use of corticosteroid treatment;
- •8. Peripheral neuropathy Grade > 2 (National Cancer Institute Common Terminology Criteria (NCI CTCAE v.4.03);
- •9. Previous beta or gamma Isotope treatment (e.g. strontium or samarium), alpha emitters are allowed;
- •10. History of severe hypersensitivity reaction (> grade 2) to polysorbate 80 containing drugs;
- •11. Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a 2-week washout period is necessary for patients who are already on these treatments);
- •12. Previous malignancy except for basal cell or squamous cell skin cancer adequately treated, or any other cancer from which the patient has been disease-free for = 5 years;
- •13. Patients with reproductive potential who do not agree to use accepted and effective method of contraception, based on the investigator’s judgment, during the study treatment period.
研究者
相似试验
已完成
3 期
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate CancerProstate CancerNCT01308567Sanofi1,168
进行中（未招募）
1 期
Cabazitaxel and Abiraterone Acetate in Patients with Metastatic Castrate-Resistant Prostate CancerMedDRA version: 14.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)prostate cancerEUCTR2011-001506-96-GBsanofi-aventis recherche et développement37
进行中（未招募）
1 期
A study of cabazitaxel to treat patients with confirmed locally advanced or metastatic Transitional Cell Carcinoma of the bladder or upper urinary tracts who have developed progressive disease within 12 months of their platinum based chemotherapyEUCTR2012-002552-16-GBniversity Hospitals Birmingham NHS Foundation Trust20
进行中（未招募）
1 期
A Phase II Study of Cabazitaxel for Patients with Breast or Lung Cancer and Recurrent or Progressive Brain Metastases (CaBaMet)breast or lung cancer with recurrent or progressive brain metastasesMedDRA version: 19.1Level: LLTClassification code 10025062Term: Lung cancer stage IVSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10006192Term: Breast cancer NOSSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10006128Term: Brain metastasesSystem Organ Class: 100000004864EUCTR2013-005545-37-DEAIO-Studien-gGmbH
进行中（未招募）
不适用
A study to evaluate the effectiveness of combination cabazitaxel and cisplatin chemotherapy before surgery for invasive bladder cancerEUCTR2011-004090-82-GBniversity Hospitals Bristol NHS Foundation Trust Research and Innovation Department30